Susquehanna International Group, LLP Annovis Bio, Inc. Transaction History
Susquehanna International Group, LLP
- $568 Billion
- Q1 2024
A detailed history of Susquehanna International Group, LLP transactions in Annovis Bio, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 72,602 shares of ANVS stock, worth $400,037. This represents 0.0% of its overall portfolio holdings.
Number of Shares
72,602
Previous 15,772
360.32%
Holding current value
$400,037
Previous $294,000
193.54%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding ANVS
# of Institutions
52Shares Held
1.2MCall Options Held
779KPut Options Held
1.77M-
Vanguard Group Inc Valley Forge, PA358KShares$1.97 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA250KShares$1.38 Million0.01% of portfolio
-
Black Rock Inc. New York, NY97.6KShares$537,9350.0% of portfolio
-
Geode Capital Management, LLC Boston, MA70.8KShares$390,0580.0% of portfolio
-
Wescott Financial Advisory Group, LLC41.6KShares$229,2540.07% of portfolio
About Annovis Bio, Inc.
- Ticker ANVS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,163,920
- Market Cap $45M
- Description
- Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...